Understanding Health Outcomes and Pharmacoeconomics

George E. MacKinnon III, PhD, RPh, FASHP
Principal, HealthKey Solutions, Inc.
Founding Dean and Professor
College of Pharmacy
Roosevelt University
Schaumburg Campus
Schaumburg, IL

C 265812

JONES & BARTLETT LEARNING
Contents

Foreword xiii
Contributors xv
Reviewers xix
About the Author xxix

SECTION I  □ Introduction to Measuring Health Status 1

CHAPTER 1  □ Introduction 3
George E. MacKinnon III, PhD, RPh, FASHP

CHAPTER 2  □ Drug Development and Approval 9
Patricia M. Finnegan, MS
George E. MacKinnon III, PhD, RPh, FASHP

Introduction 9
  □ Drug Development and Regulation at the Turn of the 20th Century 9
  □ Evolution of Drug Development and Approval 10 □ Drug Development and Approval Present and Future 10

Regulation 10
  □ Department of Health and Human Services 10 □ Evolution of Drug Regulation:
  Focus on Safety 11 □ Evaluating Safety and Efficacy 12

Sex, Age, and Racial Differences in Clinical Trials 12

Focus on Cost Control and Faster Access to New Therapies 13
CHAPTER 5  □ Overview of Statistical Analysis in Biomedical Research 57

Chenghui Li, PhD

Introduction 57

Study Design and Bias 58
  □ Study Design 58  □ Validity and Bias 59

Probability and Uncertainty 61
  □ Probabilities and Distribution 61  □ Uncertainty 66

Estimating Risk 67
  □ Relative Risk and Odds Ratio 67  □ Logistic Regression and Adjusted OR 70
  □ Survival Analysis 71

Estimating Mean Cost 75
  □ Estimating Mean Cost and Statistical Tests: Mean Cost or Median Cost? 75
  □ Transformation and Smearing 76  □ Generalized Linear Model 76
  □ Two-Part Model 77  □ Censored Cost Data 78  □ Uncertainty 79

Summary 79

References 79

SECTION II  □ Evaluating Levels of Evidence 83

CHAPTER 6  □ Randomized Controlled Trials 85

Nathaniel M. Rickles, PharmD, PhD, BCPP
Matthew Wolfe, BA

Introduction 85

Development of an RCT 87
  □ Selection of Study Participants 87  □ Determination of Sample Size 89
  □ Recruitment of Study Participants 91  □ Assignment of Study Participants 91

Consent and Ethical Considerations 94

RCT Implementation 98

RCT Analysis and Evaluation 100

Clinical and Statistical Significance 103

Summary 103

References 106
CHAPTER 7  □  Systematic Reviews and Meta-Analyses  107

Gerald E. Schumacher, PhD

Introduction 107

Comparing Narrative Review, Systematic Review, and Meta-Analysis 108

Examples of Systematic Reviews and Meta-Analyses in Drug Treatment

& Example A 110 & Example B 110 & Example C 111 & Example D 111
& Example E 111

Steps in Conducting and Interpreting Systematic Reviews and Meta-Analyses


Summary 118

References 121

CHAPTER 8  □  Medical and Prescription Claims Databases  123

Donald G. Klepser, PhD, MBA

Introduction 123

What Exactly Is a Claims Database? 124

& Enrollment File 126 & Medical Claims Databases 126 & Prescription Claims 127

What Are the Advantages and Disadvantages of Using Claims Databases? 128

& Advantages 128 & Disadvantages 129
### SECTION III □ Pharmacoeconomics 151

#### CHAPTER 10 □ Decision Analysis 153
George E. MacKinnon III, PhD, RPh, FASHP

Decision Analysis Techniques 154
- Decision Tables 154
- Decision Trees 155

References 161

#### CHAPTER 11 □ Introduction to Economic Analysis, Cost Determinants, and Modeling 163
Jaewhan Kim, PhD
Junhua Yu, PhD

Introduction 163

Types of Economic Analysis 164

Elements of Economic Analysis 165
- Perspective 165
- Cost Determinants 166
- Measuring Outcomes 166
- Discounting Cost and Outcomes 167
- Sensitivity Analysis for Uncertainty and Variability 167

Modeling in Economic Evaluations 167

Limitations of Economic Analysis 169

Additional Resources 169

#### CHAPTER 12 □ Cost-of-Illness Analysis and Budget Impact Models 171
Steven E. Marx, PharmD, RPh

Introduction 171

Cost of Illness 173

Budget Impact Models 174

Summary 177

References 178
CHAPTER 13 □ Cost-Effectiveness Analysis, Cost-Utility Analysis, and Cost-Benefit Analysis 179

Junhua Yu, PhD
Jaewhan Kim, PhD

Cost-Effectiveness Analysis 179
  □ Methods 180 □ Summary 187

Cost-Utility Analysis 187
  □ Methods 189 □ Summary 189

Cost-Benefit Analysis 189
  □ Method 191 □ Summary 191

References 192

CHAPTER 14 □ Comparative Effectiveness 195

Patrick D. Meek, PharmD, MSPH
Amy C. Renaud-Mutart, PharmD, MSPharm
Leon E. Cosier, RPh, PhD

Introduction 195

Background on CER 196

Forms of CER 197

CER and Analytic Techniques Involving Costs 200
  □ Situations in Which Comparative Effectiveness Analysis with an Economic Analysis Would Be the Best Choice 203

Impact of CER in the United States 203
  □ Use of CER Studies in International Single-Payer and Social Insurance Health Care Models 203 □ Existing Capacity for CER in the United States 204 □ Proposal to Establish a Quasi-Governmental National Comparative Effectiveness Center in the United States 204

CER and Clinical Pharmacy Practice 205

References 206

Index 207